Sugi Predict

Sugi Predict / Compounds / SCHEMBL2948034

SCHEMBL2948034

SCHEMBL2948034

O=C(O)C[C@H](CSc1ccccc1)NC(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 4/20 0.54
▸ KMT2A Q03164 2/20 0.49
▸ MDM4 O15151 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ EPHX2 P34913 1/20 0.44
▸ SLC17A5 Q9NRA2 1/20 0.44
▸ PLA2G10 O15496 1/20 0.43
▸ CASP1 P29466 1/20 0.41
▸ PLA2G2A P14555 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1955384 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL29424533 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL31470993 0.88 CASP3 (0.63) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL120580 0.88 CASP3 (0.63) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL30604630 0.88 CASP3 (0.63) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL31450834 0.88 KMT2A (0.48) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL31450833 0.87 CASP3 (0.48) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL31451006 0.87 CASP3 (0.48) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL15873350 0.87 CASP3 (0.48) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL15873353 0.87 CASP3 (0.48) CASP3KMT2AMDM4TP53EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50643-E1 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2025-10-21 — — US disclosed
EP-4556469-A1 BENZAMIDE COMPOUNDS Recurium IP Holdings, LLC (US) 2025-05-21 — — EP disclosed
EP-3740487-B1 BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV RECURIUM IP HOLDINGS LLC (US) 2025-01-08 — — EP disclosed
US-20240180899-A1 BENZAMIDE COMPOUNDS RECURIUM IP HOLDINGS, LLC 2024-06-06 — — US disclosed
US-11813259-B2 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2023-11-14 — — US disclosed
US-11813260-B1 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2023-11-14 — — US disclosed
US-11590126-B2 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2023-02-28 — — US disclosed
US-20220273666-A1 NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR RECURIUM IP HOLDINGS, LLC 2022-09-01 — — US disclosed
US-20220265834-A1 BCL-2 PROTEIN INHIBITORS RECURIUM IP HOLDINGS, LLC 2022-08-25 — — US disclosed
US-20220226314-A1 BENZAMIDE COMPOUNDS RECURIUM IP HOLDINGS, LLC 2022-07-21 — — US disclosed
US-9096625-B2 BCL-2/BCL-XL inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-08-04 — — US disclosed
WO-2014113413-A1 BCL-2BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-07-24 — — WO disclosed
US-20140199234-A1 BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-07-17 — — US disclosed
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 — — US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 — — US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 — — US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 — — US disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CASP3 27/4885KMT2A 2902/4885MDM4 4254/4885
US-11813259-B2 Benzamide compounds MKI67, TMBIM6, HDAC1 CASP3 359/4885KMT2A 1132/4885MDM4 932/4885
US-11813260-B1 Benzamide compounds MKI67, TMBIM6, HDAC1 CASP3 359/4885KMT2A 1132/4885MDM4 932/4885
US-20220265834-A1 BCL-2 PROTEIN INHIBITORS BCL2, BCL2L1, BCL2L2 CASP3 67/4885KMT2A 2119/4885MDM4 1380/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CASP3 24/4885KMT2A 2895/4885MDM4 4118/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CASP3 27/4885KMT2A 2902/4885MDM4 4254/4885
US-11590126-B2 Benzamide compounds MKI67, TMBIM6, HDAC1 CASP3 359/4885KMT2A 1132/4885MDM4 932/4885
US-20140199234-A1 BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BCL2, BCL2L2, BCL2L1 CASP3 59/4885KMT2A 1647/4885MDM4 1991/4885
US-20220273666-A1 NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR BCL2, BCL2L2, BCL2L1 CASP3 47/4885KMT2A 1466/4885MDM4 2529/4885
US-20220226314-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 CASP3 359/4885KMT2A 1132/4885MDM4 932/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR CASP3 23/4885KMT2A 2456/4885MDM4 3903/4885
US-20240180899-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 CASP3 359/4885KMT2A 1132/4885MDM4 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.